Experimental combo aims to tame aggressive lymphoma without chemo
NCT ID NCT05495464
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically modified immune cells (CAR T-cells). The goal is to see if this approach can control the cancer safely. Only 22 participants will be enrolled at a single center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acalabrutinib, rituximab, and brexucabtagene autoleucel (CAR T-cell therapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with high-risk mantle cell lymphoma, potentially improving disease control without needing long-term chemotherapy.
What could go wrong
This is a very early (Phase 1) pilot study with only 22 participants. The treatment may cause serious side effects, and it is not yet known if it will work better than standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States